|
|
 |
| |
|
|
|
Development of HCC Post HCV SVR Therapy; Data Mining Discovery (Proposal Study) |
|
|
|
PP: 53-54 |
|
|
|
doi:10.18576/ab/020205
|
|
|
|
Author(s) |
|
|
|
Abd Elrazek M Ali,
|
|
|
|
Abstract |
|
|
| The main risk of chronic HCV infection is progression to cirrhosis and its attendant complications. Curing HCV prior to the development of advanced cirrhosis results in decreased hepatocellular carcinoma rates and liver-related complications, unlike HBV, it is not common to find HCC on healthy liver of a patients with HCV infection. Recently some patients developed HCC, with or without portal vein thrombosis post SVR of new oral therapy, nevertheless hepatocellular carcinoma rates and liver-related complications, has dramatically advanced in the past 5 years. Interferon based-therapy had substantial effect on HCC. The new direct-acting antiviral agents (DAAs) yield outstanding results with >95% of patients with HCV achieving sustained virologic response (SVR) after 12 weeks of treatment. This remarkable achievement represents a major breakthrough in hepatology, unfortunately many aggressive HCCs have been reported at the end of new (DAAs), the situation have not been observed with Peg-interferon/ribavirin regimen, wondering if DAAs alter immunomodulation pathways in a way that abrogates the immune system’s ability to control small neoplastic niches (either denovo occurrence, recurrences or both of them). Unfortunately, most of the DAA trials excluded patients with HCC. |
|
|
|
|
|
|
|
